Find clinical trials

This study aims to test the effectiveness of a new and improved version (version 2) of a virtual reality intervention designed to support the social and cognitive recovery of young people with early psychosis. The study will compare version 2 with the previous version 1, to determine if the new version is more effective in improving social functioning.

This is a Phase I clinical trial evaluating an investigational treatment called IDOVImmune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.

The study is being done over 24 weeks to see whether an experimental drug called MTX-463 can slow or stop a lung disease called idiopathic pulmonary fibrosis (IPF) from worsening, in people >40 years of age who have IPF.

This study will follow-up the WITHDRAW-AF cohort, to evaluate long term outcomes of this cohort.

The main purpose of this study is to determine if XEN1101 can reduce seizure frequency in people with focal epilepsy and if it is safe to use. In this study 360 participants globally will be randomly assigned to receive either XEN1101 (25mg/day or 15mg/day) or placebo (an inactive substance) for 12 weeks, in addition to their usual anti-seizure medications.

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).